Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Subacute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 7, 2012, Pages 1044-1054

  Yanik, Gregory A ^a   Mineishi, Shin ^a   Levine, John E ^a   Kitko, Carrie L ^a   White, Eric S ^a,b   Vander Lugt, Mark T ^a   Harris, Andrew C ^a   Braun, Thomas ^b   Cooke, Kenneth R ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Bone marrow transplant; Bronchiolitis obliterans; Chronic graft versus host disease; Etanercept

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID; CREATININE; CYCLOSPORIN; ELECTROLYTE; ETANERCEPT; FLUCONAZOLE; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; ITRACONAZOLE; LEVOFLOXACIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VORICONAZOLE;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTEREMIA; CHILD; CLINICAL ARTICLE; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INJECTION SITE REACTION; LONG TERM SURVIVAL; LUNG INJURY; LUNG LAVAGE; MALE; MORBIDITY; OSTEOMYELITIS; OVERALL SURVIVAL; PNEUMONIA; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SINUSITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; VIREMIA;

ACUTE DISEASE; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; CHILD; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84862125240     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.11.031     Document Type: Article

References (73)

1. Crawford S., Longton G., Storb R. Acute graft versus host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia. Bone Marrow Transplant 1986, 104:168-175.
2. Clark J.G., Madtes D.K., Martin T.R., Hackman R.C., Farrand A.L., Crawford S.W. Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplification in the bronchoalveolar compartment. Crit Care Med 1999, 27:1800-1806.
3. Clark J.G., Hansen J.A., Hertz M.I., Parkman R., Jensen L., Peavy H.H. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993, 147:1601-1606.
4. Holland H.K., Wingard J.R., Beschorner W.E., Saral R., Santos G.W. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-versus-host disease and low serum IgG. Blood 1988, 72:621-627.
5. Schultz K.R., Green G.J., Wensley D., et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994, 84:3212-3220.
6. Crawford S.W., Pepe M., Lin D., Benedetti F., Deeg H.J. Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. Am J Respir Crit Care Med 1995, 152:690-695.
7. Philit F., Wiesendanger T., Archimbaud E., Mornex J.F., Brune J., Cordier J.F. Post-transplant obstructive lung disease (" bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995, 8:551-558.
8. Badier M., Guillot C., Delpierre S., Vanuxem P., Blaise D., Maraninchi D. Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant 1993, 12:457-461.
9. Clark J.G., Schwartz D.A., Flournoy N., Sullivan K.M., Crawford S.W., Thomas E.D. Risk factors for air-flow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987, 107:648-656.
10. Schwarer A.P., Hughes J.M.B., Trotman-Dickenson B., Krausz T., Goldman J.M. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplantation 1992, 54:1002-1008.
11. Afessa B., Litzow M.R., Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 28:425-434.
12. Cerveri I., Fulgoni P., Giorgiani G., et al. Lung function abnormalities after bone marrow transplantation in children: has the trend recently changed?. Chest 2001, 120:1900-1906.
13. Sanchez J., Torres A., Serrano J., et al. Long term follow up of immunosuppressive treatment for obstructive airway disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 20:403-408.
14. Clark J.G., Crawford S.W., Madtes D.K., Sullivan K.M. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989, 111:368-376.
15. Quigley P., Yeager A., Loughlin G. The effects of bone marrow transplantation on pulmonary function in children. Pediatr Pulmonol 1994, 18:361-367.
16. Chien J.W., Martin P.J., Flowers M.E., Nichols W.G., Clark J.G. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 33:759-764.
17. Chien J.W., Martin P.J., Gooley T.A., et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003, 168:208-214.
18. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996, 88:3230-3239.
19. Hildebrandt G.C., Olkiewicz K.M., Corrion L.A., et al. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004, 104:586-593.
20. Yanik G.A., Ho V.T., Levine J.E., et al. The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008, 112:3073-3081.
21. Wyatt S.E., Nunn P., Hows J.M., et al. Airways obstruction associated with graft-versus-host disease after bone marrow transplantation. Thorax 1984, 39:887.
22. Urbanski S.J., Kossakowska A.E., Curtis J., et al. Idiopathic small airways pathology in patients with graft-versus-host disease following allogeneic bone marrow transplantation. Am J Surg Pathol 1987, 11:965.
23. Ralph D.D., Springmeyer S.C., Sullivan K.M., Hackman R.C., Storb R., Thomas E.D. Rapidly progressive air-flow obstruction in marrow transplant recipients. Possible association between obliterative bronchiolitis and chronic graft-versus-host disease. Am Rev Respir Dis 1984, 129:641-644.
24. Cooke K.R., Yanik G. Lung injury following hematopoietic stem cell transplantation. Thomas' Hematopoietic Cell Transplantation 2009, Wiley-Blackwell, New York. F.R. Appelbaum, S.J. Forman, R.S. Negrin, K.G. Blume (Eds.).
25. Belperio J.A., Keane M.P., Burdick M.D., et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001, 108:547-556.
26. Belperio J.A., DiGiovine B., Keane M.P., et al. Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation 2002, 73:591-599.
27. Elssner A., Jaumann F., Dobmann S., et al. Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. Transplantation 2000, 70:362-367.
28. El-Gamel A., Sim E., Hasleton P., et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999, 18:828-837.
29. Piguet P.F., Collart M.A., Grau G.E., Kapanci Y., Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989, 170:655-663.
30. Piguet P., Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994, 7:515-518.
31. Engelmann H., Aderka D., Rubinstein M., et al. A tumor necrosis factor-binding protein purified to hemogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989, 264:11974-11980.
32. Gatanaga T., Hwang C.D., Kohr W., et al. Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990, 87:8781-8784.
33. Lesback M., Hanna R., Lange J.R., et al. Absolute bioavailability of TNF receptor Fusum protein following subcutaneous injection in healthy volunteers. Pharmacotherapy 1997, 17:1118.
34. Wee S., Pascual M., Eason J., et al. Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant patients who receive okt3 therapy. Transplantation 1997, 63:570-577.
35. Lovell D., Giannini E., Reiff A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763-769.
36. Moreland L., Schiff M., Baumgartner S., et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999, 130:478-486.
37. Cook D., Dimick J., Gallagher D. Etanercept in rheumatoid arthritis. N Engl J Med 1999, 340:2000-2001.
38. Moreland L., Baumgartner S., Schiff M., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997, 337:141-147.
39. Andolina M., Rabusin M., Maximova N., Di Leo G. Etanercept in graft-versus-host disease. Bone Marrow Transplant 2000, 26:929.
40. Chiang K.Y., Abhyankar S., Bridges K., Godder K., Henslee-Downey J.P. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002, 73:665-667.
41. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
42. Dudek A., Mahaseth H., DeFor T., Weisdorf D. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003, 9:657-666.
43. Ratjen F., Rjabko O., Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant 2005, 36:135-138.
44. Smith E.P., Sniecinski I., Dagis A.C., et al. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant 1998, 4:27-37.
45. Lucid C.E., Savani B.N., Engelhardt B.G., et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. Bone Marrow Transplant 2011, 46:426-429.
46. Fullmer J.J., Fan L.L., Dishop M.K., Rodgers C., Krance R. Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. Pediatrics 2005, 116:767-770.
47. Or R., Gesundheit B., Resnick I., et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 2007, 83:577-581.
48. Khalid M., Al Saghir A., Saleemi S., et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005, 25:490-493.
49. Bergeron A., Belle A., Chevret S., et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39:547-553.
50. Gottlieb A.B., Gordon K., Giannini E.H., et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011, 10:289-300.
51. Domm S., Cinatl J., Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008, 159:1217-1228.
52. Shale M.J., Seow C.H., Coffin C.S., Kaplan G.G., Panaccione R., Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010, 31:20-34.
53. Klareskog L., Gaubitz M., Rodriguez-Valverde V., et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011, 29:238-247.
54. Montiel P.M., Solis J.A., Chirinos J.A., a Casis B., Sanchez F., Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008, 28:718-720.
55. Kim Y.J., Bae S.C., Sung Y.K., et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 2010, 37:346-350.
56. Urata Y., Uesato R., Tanaka D., et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 2011, 21:16-23.
57. Li S.G. Clinical image: development of miliary tuberculosis following one intraarticular injection of etanercept. Arthritis Rheum 2011, 63:1364.
58. Veeraputhiran M., Mangan K. Sudden loss of the GVL effect following use of the TNF inhibitor infliximab in a chronic myelogenous leukemia patient with chronic GVHD. Bone Marrow Transplant 2010, 45:1113-1114.
59. Crawford S.W., Clark J.G. Bronchiolitis associated with bone marrow transplantation. Clin Chest Med 1993, 14:741-749.
60. Coker R., Laurent G. Pulmonary fibrosis: cytokines in the balance. Eur Respir J 1998, 11:1218-1221.
61. Sime P., Marr R., Gauldie D., et al. Transfer of tumor necrosis factor-a to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-b1 and myofibroblasts. Am J Pathol 1998, 153:825-832.
62. Miyazaki Y., Araki K., Vesin C., et al. Expression of a tumor necrosis factor-a transgene in murine lung causes lymphocytic and fibrosing alveolitis. J Clin Invest 1995, 96:250-259.
63. Ortiz L., Lasky J., Lungarella G., et al. Upregulation of the p75 but not the p55 TNFa receptor mRNA after silica and bleomycin exposure and protectin from lung injury in double receptor knockout mice. Am J Respir Cell Mol Biol 1999, 20:825-833.
64. Raghu G., Brown K.K., Costabel U., et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178:948-955.
65. Skert C., Damiani D., Michelutti A., et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant 2009, 44:729-737.
66. Kaminska D., Bernat B., Vakulenko O., et al. Glomerular lesion and increased cytokine gene expression in renal tissue in patients with decompensated nephrotic syndrome because of chronic GvHD. Renal Failure 2010, 32:510-514.
67. Fimiani M., De Aloe G., Cuccia A. Chronic graft versus host disease and skin. J Eur Acad Dermatol Venereol 2003, 17:512-517.
68. Ritchie D., Seconi J., Wood C., Walton J., Watt V. Prospective monitoring of tumor necrosis factor alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:706-712.
69. Toubai T., Shono Y., Nishihira J., et al. Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. Int J Lab Hematol 2009, 31:161-168.
70. Ayyildiz E., Arslan O., Topcuoglu P., et al. The effect of extracorporeal photoimmunotherapy (ECP) on serum TNF-a level in chronic graft versus host disease (GvHD). Transfus Apheresis Sci 2007, 36:79-85.
71. Fujii H., Cuvelier G., She K., et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008, 111:3276-3285.
72. Chien J.W., Zhao L.P., Hansen J.A., Fan W.H., Parimon T., Clark J.G. Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 2006, 107:2200-2207.
73. Hildebrandt G.C., Granell M., Urbano-Ispizua A., et al. Recipient NOD2/CARD15 variants: a novel independent risk factor for the development of bronchiolitis obliterans after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:67-74.